老年房颤患者口服抗凝药与急性肾损伤风险
该研究基于加拿大安大略省20,683例≥66岁房颤门诊患者,比较直接口服抗凝药与华法林相关的急性肾损伤风险。结果显示,达比加群、利伐沙班和阿哌沙班均与较低的AKI风险相关。
要点
- 与华法林相比,直接口服抗凝药与较低的AKI风险相关。
- 各直接口服抗凝药的AKI风险降低在各eGFR分层中一致。
- 华法林INR达标率≤56%者,直接口服抗凝药的AKI风险更低。
核心结论
- 直接口服抗凝药与华法林相比,与较低的急性肾损伤风险相关。
研究设计与样本
- 基于人群的队列研究,纳入2009至2017年加拿大安大略省20,683例≥66岁房颤门诊患者。
- 使用逆概率治疗加权平衡基线特征,Cox比例风险回归比较结局。
- 暴露为门诊处方华法林或直接口服抗凝药(达比加群、利伐沙班或阿哌沙班)。
主要发现
- 达比加群加权风险比0.65(95%CI 0.53-0.80),利伐沙班0.85(95%CI 0.73-0.98),阿哌沙班0.81(95%CI 0.72-0.93),均显著低于华法林。
- 各直接口服抗凝药较低的AKI风险在各eGFR分层中一致。
- 华法林INR达标率≤56%者中,各直接口服抗凝药的AKI风险显著低于华法林。
关键数值与推荐
- 主要结局为需住院的AKI,采用KDIGO阈值定义。
临床怎么用
- 老年房颤患者选择抗凝药时,可将AKI风险纳入考量,直接口服抗凝药可能优于华法林。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Anticoagulation with either a vitamin K antagonist or a direct oral anticoagulant may be associated with AKI. Our objective was to assess the risk of AKI among elderly individuals with atrial fibrillation newly prescribed a direct oral anticoagulant (dabigatran, rivaroxaban, or apixaban) versus warfarin. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Our population-based cohort study included 20,683 outpatients in Ontario, Canada, ≥66 years with atrial fibrillation who were prescribed warfarin, dabigatran, rivaroxaban, or apixaban between 2009 and 2017. Inverse probability of treatment weighting on the basis of derived propensity scores for the treatment with each direct oral anticoagulant was used to balance baseline characteristics among patients receiving each of the three direct oral anticoagulants compared with warfarin. Cox proportional hazards regression was performed in the weighted population to compare the association between the prescribed anticoagulant and the outcomes of interest. The exposure was an outpatient prescription of warfarin or one of the direct oral anticoagulants. The primary outcome was a hospital encounter with AKI, defined using Kidney Disease Improving Global Outcomes thresholds. Prespecified subgroup analyses were conducted by eGFR category and by the percentage of international normalized ratio measurements in range, a validated marker of anticoagulation control. RESULTS: Each direct oral anticoagulant was associated with a significantly lower risk of AKI compared with warfarin (weighted hazard ratio, 0.65; 95% confidence interval, 0.53 to 0.80 for dabigatran; weighted hazard ratio, 0.85; 95% confidence interval, 0.73 to 0.98 for rivaroxaban; and weighted hazard ratio, 0.81; 95% confidence interval, 0.72 to 0.93 for apixaban). In the subgroup analysis, the lower risk of AKI associated with each direct oral anticoagulant was consistent across each eGFR strata. The risk of AKI was significantly lower among users of each of the direct oral anticoagulants compared with warfarin users who had a percentage of international normalized ratio measurements ≤56%. CONCLUSIONS: Direct oral anticoagulants were associated with a lower risk of AKI compared with warfarin.
引用
- Harel Z, McArthur E, Jeyakumar N, et al. The Risk of Acute Kidney Injury with Oral Anticoagulants in Elderly Adults with Atrial Fibrillation. Clin J Am Soc Nephrol. 2021. PMID: 34407990. doi:10.2215/CJN.05920421
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。